Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

In the last decade, several antibodies targeting the inflammatory cascade, which are implicated in inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn’s diseases, have been approved and made available to patients. However, researchers say therapies can and should be more effective. In this month’s cover story, we explore how novel approaches that go beyond approved anti-inflammatory mechanisms are being pursued in IBD, but how they remain restricted to earlier stages of development.

Also in this issue, we take a look at the growing trend of subcutaneous versions of approved drugs making a mark, especially in the oncology space where checkpoint inhibitors are poised to get a second life with the approval of these new versions.

All this and the latest news and analysis on the pharmaceutical and biotech industry.

Manasi Vaidya, editor